title: [Treatment of secondary hyperparathyroidism in hemodialysed patients--paricalcitol with or without cinacalcet].
abstract: Secondary hyperparathyroidism (sHPT) is a common complication being a consequence of metabolic disorders associated with chronic kidney disease (CKD). Treatment of the sHPT should lead to calcium-phosphate management stabilization and parathyroid hormone levels reduction. The phosphate binders, synthetic vitamin D analogs and calcimimetics are used in sHPT treatment. In this paper we analyzed the results of three month paricalcitol treatment of 36 hemodialysis patients with sHPT (serum iPTH> 500 pg/ml). 11 patients have additionally received cinacalcet. Analysis of the results showes a statistically significant reduction in iPTH and alkaline phosphatase. Paricalcitol is effecitve in the tratment of SHPT with favourable profile of side effects. Alcaline phosphatase reduction may be a desirable additional therapeuctic effect. However, it appears that combined therapy with paricalcitol and cinacalcet shoud be offered to selected population of patients i.e. with hypocalcemia after calcimimetics.
authors.forename: Jacek
authors.initials: J
authors.lastname: Zawierucha
authors.forename: Jolanta
authors.initials: J
authors.lastname: Małyszko
authors.forename: Jacek
authors.initials: J
authors.lastname: Małyszko
authors.forename: Teresa
authors.initials: T
authors.lastname: Dryl-Rydzyńska
authors.forename: Tomasz
authors.initials: T
authors.lastname: Prystacki
authors.forename: Wojciech
authors.initials: W
authors.lastname: Marcinkowski
mesh_terms: D000328:Adult; D000368:Aged; D000069449:Cinacalcet / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004872:Ergocalciferols / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000097:blood; D006435:Renal Dialysis; D051436:Renal Insufficiency, Chronic / Q000150:complications*; D016896:Treatment Outcome
chemical_list: D004872:Ergocalciferols; D010281:Parathyroid Hormone; C084656:paricalcitol; D000069449:Cinacalcet